Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran

authors:

avatar Behzad Hajarizadeh 1 , *

The Kirby Institute, UNSW Sydney (University of New South Wales), Sydney, Australia

how to cite: Hajarizadeh B. Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran. Hepat Mon. 2017;17(1):e45788. https://doi.org/10.5812/hepatmon.45788.

References

  • 1.

    Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: World Health Organization; 2016.

  • 2.

    Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016;16(7). eee37234. [PubMed ID: 27642346]. https://doi.org/10.5812/hepatmon.37234.

  • 3.

    Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016;1(4):317-27. https://doi.org/10.1016/s2468-1253(16)30075-9.

  • 4.

    Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012;54(10):1465-72. [PubMed ID: 22431808]. https://doi.org/10.1093/cid/cis227.

  • 5.

    Freeman JA, Hill A. The use of generic medications for hepatitis C. Liver Int. 2016;36(7):929-32. [PubMed ID: 27306303]. https://doi.org/10.1111/liv.13157.

  • 6.

    Ravinetto R, De Weggheleire A, Dorlo TP, Francque S, Sokkab A, Pouget C, et al. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Trop Med Int Health. 2016;21(12):1490-5. [PubMed ID: 27671365]. https://doi.org/10.1111/tmi.12784.

  • 7.

    Sarpel D, Dieterich D. The use of generics to treat chronic hepatitis C: not quite ready for the big stage. Liver Int. 2016;36(7):933-5. [PubMed ID: 27306304]. https://doi.org/10.1111/liv.13155.

  • 8.

    Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepat Mon. 2016;17(1). ee44564. https://doi.org/10.5812/hepatmon.44564.

  • 9.

    Freeman JA, Sallie R, Kennedy A, Jeffreys G, Savage A, Hill AM. High Sustained Virological Response Rates using Legally Imported, Generic Direct Acting Antiviral Treatment for Hepatitis C. Hepatology. 2016;63(1 SUPP):444A.

  • 10.

    Yakoot M, Abdo AM, Yousry A, Helmy S. Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy. Drug Des Devel Ther. 2016;10:2659-67. [PubMed ID: 27601883]. https://doi.org/10.2147/DDDT.S111496.

  • 11.

    Hill AM, Golovin S, Dragunova J, Korologou-Linden RS. Virological Response rates using Generic Direct Acting Antiviral Treatment for Hepatitis C, Legally Imported into Russia. Hepatology. 2016;63(1 SUPP):1005A.

  • 12.

    Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, et al. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10(5):789-98. [PubMed ID: 27443347]. https://doi.org/10.1007/s12072-016-9755-0.

  • 13.

    Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493-505. [PubMed ID: 26754432]. https://doi.org/10.1002/hep.28446.

  • 14.

    Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430-41. [PubMed ID: 26822022]. https://doi.org/10.1002/hep.28473.

  • 15.

    Sahajian F, Bailly F, Vanhems P, Fantino B, Vannier-Nitenberg C, Fabry J, et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J Public Health (Oxf). 2011;33(2):182-92. [PubMed ID: 20876189]. https://doi.org/10.1093/pubmed/fdq071.

  • 16.

    Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15(4):250-4. [PubMed ID: 18086182]. https://doi.org/10.1111/j.1365-2893.2007.00937.x.

  • 17.

    Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016;111(2):311-9. [PubMed ID: 26451534]. https://doi.org/10.1111/add.13197.

  • 18.

    Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270-7. https://doi.org/10.1097/MEG.0b013e32832a8c4c.